SULFINYL KETIMINES

磺酰酮亚胺

• 批准号: 3196466
• 负责人: DUY H HUA
• 金额: $ 7.68万
• 依托单位: KANSAS STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-05-01 至 1993-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3196466
• 关键词: DNA; RNA; antiAIDS agent; antineoplastics; castanospermine; drug design /synthesis /production; drug metabolism; drug screening /evaluation; neoplasm /cancer pharmacology; neoplastic cell; propane; pyridoindole; quinolizine; stereoisomer; tissue /cell culture; yohimbine

In the course of studies involving the enantioselective synthesis of biologically active alkaloids, we have prepared chiral alpha-sulfinyl ketimines. The anions of these ketimines undergo in situ 1,4-addition/ring closure reactions with alpha-ene esters, 1,3-diiodopropane, and 3-chloro-2- chloromethylpropene. We propose to study the asymmetric addition reactions of the anions of various chiral alpha-sulfinyl ketimines and substituted acyclic and cyclic alpha-ene esters, and other electrophiles, and the stereoselective reduction of the resulted beta-sulfinyl enamides and enamines. The utilization of these reactions in the asymmetric syntheses of indolizidines [e.g., (+)-castanospermine and (-)-slaframine], quinolizidines [e.g., (-)-lupinine], pyrrolizidines [e.g., (+)-yohimbine and 18,19-dihydrousambarine], and beta-carboline alkaloids [e.g., (-)- emetine] will be studies. The synthesized natural products, their synthetic intermediates, and analogs will be tested for antitumor activity using in vitro tissue culture systems in Dr. Dolores Takemoto's laboratory (co-investigator), and anti-AIDS activities in Dr. V.L. Narayanan's laboratory, Drug Synthesis & Chemistry Branch, National Cancer Institute. The proposed synthetic schemes are general and should provide many useful biologically active synthetic intermediates and analogues. The cytotoxic activity in vitro against cancer cells (P388, P815, and L1210 cells), the toxicity towards normal cells, and the mechanism of actions (in vitro; DNA, RNA, and protein inhibitions) of these compounds will be studied.

在涉及对映选择性合成 生物活性生物碱，我们已经制备了手性α-亚磺酰基 酮亚胺。 这些酮亚胺的阴离子进行原位1，4-加成/环 与α-烯酯、1，3-二碘丙烷和3-氯-2- 氯甲基丙烯 我们建议研究不对称加成反应 各种手性α-亚磺酰基酮亚胺和取代的 无环和环状α-烯酯和其它亲电试剂，以及 立体选择性还原所得β-亚磺酰基酰胺， 烯胺 这些反应在不对称合成中的应用 吲哚嗪[例如，（+）-栗精胺和（-）-slaframine]， 喹嗪[例如，（-）-羽扇豆碱]、吡咯烷[例如，（+）-育亨宾 和18，19-二氢乌杉碱]，和β-咔啉生物碱[例如，(-)- 将是研究。 合成的天然产物， 将测试合成中间体和类似物的抗肿瘤活性 在多洛雷斯·竹本博士的实验室里使用体外组织培养系统 （共同研究者），以及V.L.博士的抗艾滋病活动纳拉亚南 国家癌症研究所药物合成与化学分支实验室。 建议的合成方案是通用的，并应提供许多有用的 生物活性合成中间体和类似物。 细胞毒性 体外抗癌细胞（P388、P815和L1210细胞）的活性， 对正常细胞的毒性和作用机制（体外; DNA， RNA和蛋白质抑制）的这些化合物将进行研究。